Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	565.44B -11.7%
Revenue (ttm)	1.45T +7.1%
Net Income	93.70B +37.7%
EPS	14,102.68 +37.4%
Shares Out	6.63M
PE Ratio	6.05
Forward PE	6.29
Dividend	1,650.49 (1.93%)
Ex-Dividend Date	Mar 11, 2026

Volume	20,573
Open	83,000
Previous Close	85,300
Day's Range	79,500 - 83,100
52-Week Range	79,500 - 121,845
Beta	0.07
Analysts	Strong Buy
Price Target	145,000.00 (+81.93%)
Earnings Date	Jul 27, 2026

About Dialog Axiata

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 83
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2025, Dong-A Socio Holdings's revenue was 1.43 trillion, an increase of 7.24% compared to the previous year's 1.33 trillion. Earnings were 90.94 billion, an increase of 56.74%.

Analyst Summary

According to 3 analysts, the average rating for 000640 stock is "Strong Buy." The 12-month stock price target is ₩145,000, which is an increase of 81.93% from the latest price.

Price Target

₩145,000

(81.93% upside)

Analyst Consensus: Strong Buy